IMGN - Chardan sees 43% upside in Invitae in premarket analyst action March, 04 2019 09:04 AM ImmunoGen Inc. Invitae (NYSE:NVTA) initiated with Buy rating and $29 (43% upside) price target at Chardan Capital Markets. Shares up 2% premarket. More news on: Invitae, ImmunoGen, Inc., Zoetis, Stocks on the move, Healthcare stocks news, Read more ...